Rosetta Genomics (Rosetta Genomics) Cash-to-Debt : 0.54 (As of Jun. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rosetta Genomics's cash to debt ratio for the quarter that ended in Jun. 2017 was 0.54.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Rosetta Genomics couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2017.

The historical rank and industry rank for Rosetta Genomics's Cash-to-Debt or its related term are showing as below:

ROSGQ's Cash-to-Debt is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.32
* Ranked among companies with meaningful Cash-to-Debt only.

Rosetta Genomics Cash-to-Debt Historical Data

The historical data trend for Rosetta Genomics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rosetta Genomics Cash-to-Debt Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.62

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	54.80	40.47	1.62	0.54

Competitive Comparison of Rosetta Genomics's Cash-to-Debt

For the Diagnostics & Research subindustry, Rosetta Genomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Cash-to-Debt falls into.

Rosetta Genomics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Rosetta Genomics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.163	/	(0.055	+	3.74)
	=	1.62

Rosetta Genomics's Cash to Debt Ratio for the quarter that ended in Jun. 2017 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.325	/	(0.055	+	2.394)
	=	0.54

Rosetta Genomics (OTCPK:ROSGQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Rosetta Genomics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Executives

Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd.	10 percent owner	C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458

Rosetta Genomics (Rosetta Genomics) Headlines

From GuruFocus

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

By gurufocus • 12-09-2008